{
      "Rank": 133,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Three Intrathecal administrations of NurOwn\u00ae (MSC-NTF cells) at bi-monthly intervals",
            "Three Intrathecal administrations of Placebo at bi-monthly intervals"
      ],
      "ArmGroupInterventionName": [
            "Biological: NurOwn\u00ae (MSC-NTF cells)",
            "Other: Bone Marrow aspiration",
            "Other: Placebo",
            "Other: Bone Marrow aspiration"
      ],
      "ArmGroupLabel": [
            "NurOwn\u00ae (MSC-NTF cells)",
            "Placebo"
      ],
      "ArmGroupType": [
            "Active Comparator",
            "Placebo Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT03280056"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "This study will evaluate the safety and efficacy of repeated administration of NurOwn\u00ae (MSC-NTF cells) therapy, which is based on transplantation of autologous bone marrow derived mesenchymal stromal cells (MSC), which are enriched from the patient's own bone marrow, propagated ex vivo and induced to secrete Neurotrophic factors (NTFs).\n\nThe autologous NurOwn\u00ae (MSC-NTF cells) are back-transplanted into the patient intrathecally by standard lumbar puncture where neurons and glial cells are expected to take up the neurotrophic factors secreted by the transplanted cells"
      ],
      "BriefTitle": [
            "Safety and Efficacy of Repeated Administrations of NurOwn\u00ae in ALS Patients"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "OTHER"
      ],
      "CollaboratorName": [
            "California Institute for Regenerative Medicine (CIRM)"
      ],
      "CompletionDate": [
            "October 30, 2020"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Amyotrophic Lateral Sclerosis (ALS)"
      ],
      "ConditionAncestorId": [
            "D000019636",
            "D000009422",
            "D000009468",
            "D000013118",
            "D000002493",
            "D000057177",
            "D000057165",
            "D000008659"
      ],
      "ConditionAncestorTerm": [
            "Neurodegenerative Diseases",
            "Nervous System Diseases",
            "Neuromuscular Diseases",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC23",
            "All",
            "BC10",
            "BC18",
            "Rare"
      ],
      "ConditionBrowseBranchName": [
            "Symptoms and General Pathology",
            "All Conditions",
            "Nervous System Diseases",
            "Nutritional and Metabolic Diseases",
            "Rare Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis"
      ],
      "ConditionBrowseLeafId": [
            "M14567",
            "M18031",
            "M3176",
            "M20711",
            "M11563",
            "M15067",
            "M4894",
            "M27912",
            "M27900",
            "M10791",
            "T4699",
            "T349"
      ],
      "ConditionBrowseLeafName": [
            "Sclerosis",
            "Motor Neuron Disease",
            "Amyotrophic Lateral Sclerosis",
            "Neurodegenerative Diseases",
            "Neuromuscular Diseases",
            "Spinal Cord Diseases",
            "Central Nervous System Diseases",
            "TDP-43 Proteinopathies",
            "Proteostasis Deficiencies",
            "Metabolic Diseases",
            "Primary Lateral Sclerosis",
            "Amyotrophic Lateral Sclerosis"
      ],
      "ConditionBrowseLeafRelevance": [
            "low",
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "high"
      ],
      "ConditionMeshId": [
            "D000016472",
            "D000000690"
      ],
      "ConditionMeshTerm": [
            "Motor Neuron Disease",
            "Amyotrophic Lateral Sclerosis"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [
            "Randomized, Double-Blind, Placebo-Controlled Multicenter Study"
      ],
      "DesignMasking": [
            "Quadruple"
      ],
      "DesignMaskingDescription": [
            "This is a double-blind study where the investigators, participants and all sponsor and CRO personnel involved in the conduct, data management or analysis of the study will remain blinded to the treatment assignments"
      ],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Care Provider",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [
            "Neurotrophic factors (NTFs) are potent survival factors for embryonic, neonatal, and adult neurons and are considered potential therapeutic candidates for ALS. Delivery of multiple NTFs to the immediate environment of afflicted neurons in ALS patients is expected to improve their survival and thus slow down disease progression and alleviate symptoms. NTF-secreting mesenchymal stromal cells (MSC-NTF cells) are a novel cell-therapeutic approach aimed at effectively delivering NTFs directly to the site of damage in ALS patients.\n\nParticipants meeting the inclusion and exclusion criteria will be randomized and will undergo bone-marrow aspiration. MSC of the participants randomized to the treatment group will be induced into MSC-NTF cells. Participants will undergo a total of three intrathecal (IT) transplantations with NurOwn\u00ae (MSC-NTF cells) or matching placebo at three bi-monthly intervals"
      ],
      "DispFirstPostDate": [
            "October 5, 2021"
      ],
      "DispFirstPostDateType": [
            "Actual"
      ],
      "DispFirstSubmitDate": [
            "October 3, 2021"
      ],
      "DispFirstSubmitQCDate": [
            "October 3, 2021"
      ],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.\nHaving onset of ALS disease symptoms, including limb weakness within 24 months at the Screening Visit.\nALSFRS-R \u2265 25 at the screening Visit.\nUpright slow vital capacity (SVC) measure \u2265 65% of predicted for gender, height, and age at the screening Visit.\nRapid progressors\nParticipants taking a stable dose of Riluzole are permitted in the study\nCitizen or permanent resident of the United States or Canadian citizen able to travel to a US site for all follow-up study visits\n\nExclusion Criteria:\n\nPrior stem cell therapy of any kind\nHistory of autoimmune or other serious disease (including malignancy and immune deficiency) that may confound study results\nCurrent use of immunosuppressant medication or anticoagulants (per Investigator discretion)\nExposure to any other experimental agent or participation in an ALS clinical trial within 30 days prior to Screening Visit\nUse of RADICAVA (edaravone injection) within 30 days of screening or intent to use edaravone at any time during the course of the study including the follow up period\nUse of non-invasive ventilation (BIPAP), diaphragm pacing system or invasive ventilation (tracheostomy)\nFeeding tube\nPregnant women or women currently breastfeeding"
      ],
      "EnrollmentCount": [
            "263"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [
            "No"
      ],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "NurOwn\u00ae (MSC-NTF cells)",
            "Placebo",
            "NurOwn\u00ae (MSC-NTF cells)",
            "Placebo"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [
            "Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors",
            "Placebo",
            "Bone Marrow aspiration"
      ],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "NurOwn\u00ae (MSC-NTF cells)",
            "Placebo",
            "Bone Marrow aspiration"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Biological",
            "Other",
            "Other"
      ],
      "IsFDARegulatedDevice": [
            "No"
      ],
      "IsFDARegulatedDrug": [
            "Yes"
      ],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [
            "MSC",
            "Autologous",
            "Neurotrophic factors"
      ],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "October 6, 2021"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "October 5, 2021"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Brainstorm-Cell Therapeutics"
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Irvine",
            "Los Angeles",
            "San Francisco",
            "Boston",
            "Worcester",
            "Rochester"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States"
      ],
      "LocationFacility": [
            "University of California Irvine Alpha Stem Cell Clinic",
            "Cedars-Sinai Medical Center",
            "California Pacific Medical Center",
            "Massachusetts General Hospital",
            "University of Massachusetts Medical School",
            "Mayo Clinic"
      ],
      "LocationState": [
            "California",
            "California",
            "California",
            "Massachusetts",
            "Massachusetts",
            "Minnesota"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "92697",
            "90048",
            "94115",
            "02115",
            "01655",
            "55905"
      ],
      "MaximumAge": [
            "60 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn\u00ae (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Brainstorm-Cell Therapeutics"
      ],
      "OrgStudyId": [
            "BCT-002-US"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Massachusetts General Hospital",
            "UMass Medical School",
            "Mayo Clinic",
            "UC Irvine",
            "California Pacific Medical Center (CPM) Research Institute",
            "Cedars-Sinai Medical Center"
      ],
      "OverallOfficialName": [
            "Merit E. Cudkowicz, MD",
            "Robert H. Brown, MD, PhD",
            "Anthony J. Windebank, MD",
            "Namita A. Goyal, MD",
            "Robert G. Miller, MD",
            "Robert Baloh, MD, Ph.D."
      ],
      "OverallOfficialRole": [
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator",
            "Principal Investigator"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 3"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "October 30, 2020"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "To determine efficacy and safety of repeat intrathecal injections of NurOwn\u00ae as compared to Placebo given three times two months apart to participants with Amyotrophic Lateral Sclerosis"
      ],
      "PrimaryOutcomeMeasure": [
            "To evaluate the efficacy and safety of NurOwn\u00ae (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)"
      ],
      "PrimaryOutcomeTimeFrame": [
            "28 weeks following the first treatment"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "To evaluate biomarkers (such as cell-secreted neurothrophic factors, inflammatory factors, and cytokines in pg/ml) in the cerebrospinal fluid (CSF) as well as in serum samples throughout the study to evaluate their relationship to treatment with NurOwn\u00ae (MSC-NTF cells)"
      ],
      "SecondaryOutcomeMeasure": [
            "Biomarkers"
      ],
      "SecondaryOutcomeTimeFrame": [
            "Through selected post-treatment time points up to 20 weeks post transplant"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "August 28, 2017"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "October 2021"
      ],
      "StdAge": [
            "Adult"
      ],
      "StudyFirstPostDate": [
            "September 12, 2017"
      ],
      "StudyFirstPostDateType": [
            "Actual"
      ],
      "StudyFirstSubmitDate": [
            "August 29, 2017"
      ],
      "StudyFirstSubmitQCDate": [
            "September 10, 2017"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 10, 2022"
      ],
      "WhyStopped": []
}